{
    "nctId": "NCT02526823",
    "officialTitle": "Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma",
    "inclusionCriteria": "1. Primary B-NHL, PTCL (ALK+ anaplastic large cell lymphoma and NK(natural killer cell )/T cell lymphoma were excluded) or HL patients confirmed by histopathology;\n2. Ages \u226518 years old, \\< 80 years old;\n3. ECOG (Eastern Cooperative Oncology Group\uff09score: 0-2\n4. At least one measurable lesion;\n5. Expected survival time\u22653 months;\n6. Liver function: transaminase\u22642.5\u00d7 upper limit of normal value\uff0cbilirubin\u22641.5\u00d7upper limit of normal value;\n7. Renal function: serum creatinine is 44-133 mmol/L;\n8. Routine blood test\uff1aWBC\u22653.0\u00d7109/L\uff0cNeutrophils\u22651.5\u00d7109/L\uff0cHb\u2265100g/L\uff0cPlatelet\u226580\u00d7109/L\uff1b LVEF\u226550%;\n9. New York Heart Association (NYHA) heart function classification is I-II grade\n10. signed informed consent.\n* Must have minimum age of 18 Years\n* Must have maximum age of 80 Years",
    "exclusionCriteria": "1. Patients with severe complications or severe infection;\n2. Invasion of central nervous system;\n3. Patients with severe heart disease history, including ventricular tachycardia (VT), atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart failure (CHF), coronary heart disease patients needed therapy;\n4. patients with severe allergic constitution, or those who are allergic to or intolerant of drug composition in chemotherapy regimens; with other malignant tumors in the past 5 years;\n5. patients received doxorubicin therapy, total cumulative dose of adriamycin was more than 300 mg/m2, total cumulative dose of epirubicin was more than 450 mg/m2;\n6. Patients participate in other clinical studies;\n7. Other patients who are not suitable for the study."
}